Vorinostat-loaded titanium oxide nanoparticles (anatase) induce G2/M cell cycle arrest in breast cancer cells via PALB2 upregulation

Abdel-Ghany, Shaimaa; Raslan, Sara; Tombuloğlu, Hüseyin; Shamseddin, Aly; Cevik, Emre; Said, Osama A. M.; Madyan, Engy F; Şenel, Mehmet; Bozkurt, Ayhan; Rehman, Suriya; Sabit, Hussein

doi:10.1007/s13205-020-02391-2

Cited by 23 publications

(12 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The HDAC catalytic activity inhibition by SAHA is based on its binding to the zinc ion located in the enzyme catalytic domain [ 58 , 94 ]. It has been demonstrated that SAHA shows the anti-proliferative acitivity of human cancer cell lines [ 95 , 96 , 97 ], including BC [ 98 , 99 , 100 ].…”

Section: Saha and Breast Cancermentioning

confidence: 99%

See 1 more Smart Citation

Vorinostat (SAHA) and Breast Cancer: An Overview

Wawruszak

Borkiewicz

Okon

et al. 2021

Cancers

View full text Add to dashboard Cite

Vorinostat (SAHA), an inhibitor of class I and II of histone deacetylases, is the first histone deacetylase inhibitor (HDI) approved for the treatment of cutaneous T-cell lymphoma in 2006. HDIs are promising anticancer agents that inhibit the proliferation of many types of cancer cells including breast carcinoma (BC). BC is a heterogeneous disease with variable biological behavior, morphological features, and response to therapy. Although significant progress in the treatment of BC has been made, high toxicity to normal cells, serious side effects, and the occurrence of multi-drug resistance limit the effective therapy of BC patients. Therefore, new active agents which improve the effectiveness of currently used regimens are highly needed. This manuscript analyzes preclinical and clinical trials data of SAHA, applied individually or in combination with other anticancer agents, considering different histological subtypes of BC.

show abstract

Section: Saha and Breast Cancermentioning

confidence: 99%

“…It has been demonstrated that partner and localizer of BRCA2 (PLAB2) gene expression was upregulated in ERL and SAHA-loaded TiO 2 NPs compared with control cells. Summarizing TiO 2 NPs can be used as a nanocarrier for chemotherapy drugs like ERL or SAHA [ 100 ].…”

Section: Saha and Drug Carriersmentioning

confidence: 99%

Vorinostat (SAHA) and Breast Cancer: An Overview

Wawruszak

Borkiewicz

Okon

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…The decreased hypoxia was correlated with a reduction in the radiation challenges and was therefore an enhanced antitumor influence [ 29 ]. Linking or encapsulating drug-loaded NPs to the target cells may lead to toxicity and may change the natural physiological capabilities in preserving homeostasis [ 30 ].…”

Section: Resultsmentioning

confidence: 99%

Ultrasonic Synthesis and Biomedical Application of Mn0.5Zn0.5ErxYxFe2−2xO4 Nanoparticles

et al. 2021

Self Cite

View full text Add to dashboard Cite

In the present study, biocompatible manganese nanoparticles have been linked with zinc and iron molecules to prepare different derivatives of Mn0.5Zn0.5ErxYxFe2−2xO4 NPs (x = 0.02, 0.04, 0.06, 0.08, 0.10), using an ultrasonication approach. The structure, surface morphology, and chemical compositions of Mn0.5Zn0.5ErxYxFe2−2xO4 NPs were elucidated by X-ray diffractometer (XRD), High-resolution transmission electron microscopy (HR-TEM), scanning electron microscope (SEM), and Energy Dispersive X-Ray Analysis (EDX) techniques. The bioactivity of Mn0.5Zn0.5ErxYxFe2−2xO4 NPs on normal (HEK-293) and (HCT-116) colon cancer cell line was evaluated. The Mn0.5Zn0.5ErxYxFe2−2xO4 NPs treatment post 48 h resulted in a significant reduction in cells (via MTT assay, having an IC50 value between 0.88 µg/mL and 2.40 µg/mL). The specificity of Mn0.5Zn0.5ErxYxFe2−2xO4 NPs were studied by treating them on normal cells line (HEK-293). The results showed that Mn0.5Zn0.5ErxYxFe2−2xO4 NPs did not incur any effect on HEK-293, which suggests that Mn0.5Zn0.5ErxYxFe2−2xO4 NPs selectively targeted the colon cancerous cells. Using Candida albicans, antifungal activity was also studied by evaluating minimum inhibitory/fungicidal concentration (MIC/MFC) and the effect of nanomaterial on the germ tube formation, which exhibited that NPs significantly inhibited the growth and germ tube formation. The obtained results hold the potential to design nanoparticles that lead to efficient bioactivity.

show abstract

“…Currently, about 40 clinical trials are in the recruitment phase (the most recent are NCT04308330, NCT04339751, NCT03803605, NCT03056495, NCT02638090, NCT04357873, NCT03167437, NCT03843528, NCT03842696) for a wide variety of diseases. Furthermore, a broad spectrum of datasets present in literature describe and demonstrate the multiple epigenetic roles of vorinostat in cancer and other disorders, as most recently reported in [ 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 ].…”

Section: (Poly)phenolic Compoundsmentioning

confidence: 98%

Marine-Derived Secondary Metabolites as Promising Epigenetic Bio-Compounds for Anticancer Therapy

et al. 2020

View full text Add to dashboard Cite

Sessile organisms such as seaweeds, corals, and sponges continuously adapt to both abiotic and biotic components of the ecosystem. This extremely complex and dynamic process often results in different forms of competition to ensure the maintenance of an ecological niche suitable for survival. A high percentage of marine species have evolved to synthesize biologically active molecules, termed secondary metabolites, as a defense mechanism against the external environment. These natural products and their derivatives may play modulatory roles in the epigenome and in disease-associated epigenetic machinery. Epigenetic modifications also represent a form of adaptation to the environment and confer a competitive advantage to marine species by mediating the production of complex chemical molecules with potential clinical implications. Bioactive compounds are able to interfere with epigenetic targets by regulating key transcriptional factors involved in the hallmarks of cancer through orchestrated molecular mechanisms, which also establish signaling interactions of the tumor microenvironment crucial to cancer phenotypes. In this review, we discuss the current understanding of secondary metabolites derived from marine organisms and their synthetic derivatives as epigenetic modulators, highlighting advantages and limitations, as well as potential strategies to improve cancer treatment.

show abstract

Vorinostat-loaded titanium oxide nanoparticles (anatase) induce G2/M cell cycle arrest in breast cancer cells via PALB2 upregulation

Cited by 23 publications

References 48 publications

Vorinostat (SAHA) and Breast Cancer: An Overview

Vorinostat (SAHA) and Breast Cancer: An Overview

Ultrasonic Synthesis and Biomedical Application of Mn0.5Zn0.5ErxYxFe2−2xO4 Nanoparticles

Marine-Derived Secondary Metabolites as Promising Epigenetic Bio-Compounds for Anticancer Therapy

Contact Info

Product

Resources

About